Malignant hyperthermia and day stay surgery

Anaesthesia and Intensive Care

Volumn 34, Issue 1, 2006, Pages 40-45

  Pollock, Neil ^a   Langton, E ^b   McDonnell, N ^c   Tiemessen, J ^a   Stowell, K ^d  

^a PALMERSTON NORTH HOSPITAL   (New Zealand)

^b WELLINGTON HOSPITAL   (New Zealand)

^c WAIKATO HOSPITAL   (New Zealand)

^d MASSEY UNIVERSITY   (New Zealand)

Author keywords

Anaesthesia; Complications; Day stay surgery; Malignant hyperthermia

Indexed keywords

ALFENTANIL; ANTIEMETIC AGENT; FENTANYL; HYPERTENSIVE FACTOR; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PROPOFOL; REMIFENTANIL; SEROTONIN 3 ANTAGONIST;

ADOLESCENT; ADULT; AGED; AMBULATORY SURGERY; ANESTHESIOLOGICAL TECHNIQUES; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENERAL ANESTHESIA; HOSPITAL ADMISSION; HUMAN; MALIGNANT HYPERTHERMIA; MEDICAL AUDIT; MINOR SURGERY; PATIENT MONITORING; PATIENT SAFETY; PEROPERATIVE CARE; POSTANESTHESIA CARE; PROSPECTIVE STUDY; REGIONAL ANESTHESIA; SURGICAL PATIENT; SURGICAL TECHNIQUE;

EID: 33244464082     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0603400114     Document Type: Article

References (23)

1. Mauritz W, Hackl W, Winkler M. Malignant hyperthermia: state of the art. Acta Anaesthesiol Scand 1997; 111 Suppl:310-312.
2. Yentis SM, Levine MF, Hartley EJ. Should all children with suspected or confirmed malignant hyperthermia susceptibility be admitted after surgery? A 10-year review. Anesth Analg 1992; 75:345-350.
3. Pollock N, Langton E, Stowell K, Simpson C, McDonnell N. Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients. Anaesth Intensive Care 2004; 32:502-509.
4. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Anonymous. Br J Anaesth 1984; 56:1267-1269.
5. Robinson RL, Hopkins PM. A breakthrough in the genetic diagnosis of malignant hyperthermia. Br J Anaesth 2001; 86:166-168.
6. Ben-David B, Solomon E, Levin H, Admoni H, Goldik P, Intrathecal fentanyl with small-dose dilute bupivacaine: better anaesthesia without prolonging recovery. Anesth Analg 1997; 85:560-565.
7. Larach MG, Localio AR, Allen GC et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80:771-779.
8. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything alright? Interpreting zero numerators. JAMA 1983; 249:1743-1745.
9. Elliott RA, Payne K, Moore JK et al. Clinical and economic choices in anaesthesia for day surgery: A prospective randomised controlled trial. Anaesthesia 2003; 58:412-421.
10. White PF. Ambulatory anaesthesia - a perspective for the future. Curr Opinion Anesth 1997; 10:407-409.
11. Gupta A, Stierer T, Zuckerman R, Sakima N, Parker SD, Fleisher LA. Comparison of recovery profile after ambulatory anesthesia with propofol, isoflurane, sevoflurane and desflurane: A systematic review. Anesth Analg 2000; 98:632-641.
12. Rognas LK, Elkjaer P, Anaesthcsia in day case laparoscopic female sterilization: a comparison of two anaesthetic methods. Acta Anaesthesiol Scand 2004; 48:899-902.
13. Erhan E, Ugur G, Alper I, Gunsen I, Ozyar B. Tracheal intubation without muscle relaxants: remifentanil or alfentanil in combination with propofol. Eur J Anaesthesiol 2003; 20:37-43.
14. Alper I, Erhan E, Ugur G, Ozyar B. Remifentanil versus alfentanil in total intravenous anaesthesia for day case surgery. Eur J Anaesthesiol 2003; 20:61-64.
15. Lichtor JL, Alessi R, Lane BS. Sleep tendency as a measure of recovery after drugs used for ambulatory surgery. Anesthesiology 2002; 96:878-883.
16. Tesniere A, Servin F. Intravenous techniques in ambulatory anesthesia. Anesthesiol Clin North Am 2003; 21:273-288.
17. Watson CB, Reierson N, Norfleet EA. Clinically significant muscle weakness induced by oral dantrolene sodium prophylaxis for malignant hyperthermia. Anesthesiology 1986; 65:312-314.
18. Hackl W, Mauritz W, Winkler M, Sporn P, Steinbereithner K. Anaesthesia in malignant hyperthermia-susceptible patients without dantrolene prophylaxis: a report of 30 cases. Acta Anaesthesiol Scand 1990; 34:534-537.
19. Cunliffe M, Lerman J, Britt BA. Is prophylactic dantrolene indicated for MHS patients undergoing elective surgery? Anesth Analg 1987; 66:S35.
20. Standards for day-stay and rooms/office based surgery and other procedures 2005: Standards New Zealand http://spex.standards.co.nz/drafts.jsp
21. Beldavs J, Small V, Cooper D, Britt BA. Postoperative malignant hyperthermia: a case report. Can Anaesth Soc J 1971; 18:202-212.
22. Schulte-Sasse U, Hess W, Eberlein HJ. Postoperative malignant hyperthermia and dantrolene therapy. Can Anaesth Soc J 1983; 30:635-640.
23. Kripke BJ, Blanck TJ, Sizemore DA et al. Association of postanaesthetic hyperthermia with abnormal muscle characteristics: a case report. Can Anaesth Soc J 1983; 30:290-294.